Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 3/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5328599 | 0.87 | DRD2 (0.51) | DRD2PRMT5WDR77SLC18A3DRD4 | |
| SCHEMBL5323533 | 0.82 | DRD2 (0.49) | DRD2SLC18A3SLC6A2 | |
| SCHEMBL5327786 | 0.82 | DRD2 (0.54) | DRD2SLC18A3 | |
| SCHEMBL5327735 | 0.82 | DRD2 (0.54) | DRD2SLC18A3DRD4 | |
| SCHEMBL5327743 | 0.81 | DRD2 (0.53) | DRD2SLC18A3DRD4 | |
| Trifluoroacetic Acid SCHEMBL5455282 | 0.79 | DRD2 (0.43) | DRD2SLC18A3TAAR1KDM1A | |
| SCHEMBL239790 | 0.76 | HTR2C (0.64) | DRD2SLC18A3KDM1AMAOAMAOB | |
| SCHEMBL14386902 | 0.75 | KMT2A (0.53) | DRD2TDP1 | |
| Hydrochloric Acid SCHEMBL2800981 | 0.74 | HTR2C (0.65) | DRD2SLC18A3KDM1AMAOAMAOB | |
| SCHEMBL5462799 | 0.74 | OPRL1 (0.36) | DRD2PRMT5WDR77SLC18A3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTCA N.V. (BE) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | CCR2, CCR1, CCR5 | DRD2 284/4885PRMT5 1953/4885WDR77 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.